Bio-path Holdings Stock News

Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers

Bio-Path Holdings Inc (NASDAQ: BPTH) shares are trading higher in Tuesday's after-hours session following the company's BP1003 data presentation at the 2022 American Association for Cancer Research

Bio-Path Holdings, Inc. (NASDAQ: BPTH) Q4 2021 earnings call dated Mar. 11, 2022 Corporate Participants: Will O’Connor — Investor Relations Peter Nielsen — President, Chief Executive Officer and Chief Financial Officer Anthony Price — Senior Vice […] The post Bio-Path Holdings, Inc. (BPTH) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Bio-Path Holdings (NASDAQ: BPTH ) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bio-Path Holdings missed estimated earnings by 84.37%, reporting … Full story available on Benzinga.com

Bio-Path press release (BPTH): FY GAAP EPS of -$1.55 misses by $0.27.As of December 31, 2021, the company had cash of $23.8M; Net cash used in operating activities for the year…

Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET

Bio-Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q4 2021 Results - Earnings Call Transcript

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to de

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place in Atlanta, GA on April 8-13, 2022.

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to deve

HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a

HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.

HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a